Armata Pharmaceuticals Announced Positive Topline Results From Its Phase 1B/2A Disarm Trial Which Evaluated Ap-sa02, A Novel Intravenous Administered Multi-phage Therapeutic For The Treatment Of Staphylococcus Aureus Bacteremia, In The Intent-to-treat Pop